Olmesartan Medoxomil (20mg) + Metoprolol Succinate (50mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) antihypertensive agent containing an angiotensin II receptor blocker (ARB), Olmesartan Medoxomil, and a beta-1 selective adrenergic blocker, Metoprolol Succinate (extended-release). This combination provides complementary mechanisms for blood pressure control by blocking the renin-angiotensin-aldosterone system (RAAS) and reducing sympathetic nervous system activity. It is indicated for the management of essential hypertension where single-agent therapy is insufficient. The combination offers improved efficacy, potential for better compliance, and a favorable side effect profile compared to higher doses of monotherapy.

The combination exerts a dual antihypertensive effect. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction, aldosterone secretion, and sympathetic activation. Metoprolol succinate is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and renin release from the kidneys. Together, they inhibit both the RAAS and sympathetic nervous system, leading to reduced peripheral vascular resistance and cardiac output.